VIDEO: Seladelpar improves markers of cholestasis in primary biliary cholangitis

VIDEO: Seladelpar improves markers of cholestasis in primary biliary cholangitis

In a video exclusive, Marlyn Mayo, MD, of the University of Texas Southwestern Medical Center, reported long-term treatment with seladelpar was safe and well-tolerated in reducing markers of cholestasis and hepatocellular injury.Mayo said seladelpar, overall, has “very safe and strong efficacy that gets even stronger in the second year.”Read More

Share on facebook
Share on twitter
Share on linkedin